Compare RDWR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDWR | VRDN |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2000 | 2014 |
| Metric | RDWR | VRDN |
|---|---|---|
| Price | $27.90 | $16.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $32.50 | ★ $35.46 |
| AVG Volume (30 Days) | 199.4K | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $10.65 | $13.73 |
| Revenue Next Year | $8.62 | $279.00 |
| P/E Ratio | $59.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.68 | $12.83 |
| 52 Week High | $30.57 | $34.29 |
| Indicator | RDWR | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 46.13 |
| Support Level | $23.64 | $15.68 |
| Resistance Level | $29.15 | $19.72 |
| Average True Range (ATR) | 0.98 | 0.91 |
| MACD | 0.06 | 0.49 |
| Stochastic Oscillator | 60.45 | 43.84 |
Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.